• 1
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al, for the Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 198492.
  • 2
    McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004; 363: 461.
  • 3
    Sakai F, Noma S, Kurihara Y, Yamada H, Azuma A, Kudoh S, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis. Mod Rheumatol 2005; 15: 1739.
  • 4
    Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40: 182937.
  • 5
    Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 1437.
  • 6
    PharMetrics patient-centric database. Watertown (MA): PharMetrics, Inc. 2005.
  • 7
    Suissa S, Ernst P, Kezouh A, Bitton A, Hudson M. Newer disease modifying anti-rheumatic drugs (DMARDs) and the risk of serious hepatic adverse events in rheumatoid arthritis. Am J Med 2004; 117: 8792.
  • 8
    Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 67780.
  • 9
    Suissa S. Novel approaches to pharmacoepidemiological study design and statistical analysis. In: StromB, editor. Pharmacoepidemiology. New York: John Wiley & Sons; 2000. p. 785805.
  • 10
    Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Hagerstown (MD): Lippincott-Raven; 1998.
  • 11
    Kalden JR, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 2003; 48: 151320.
  • 12
    Goldkind L, Simon LS. FDA meeting March 2003: update on the safety of new drugs for rheumatoid arthritis. Part III. Safety and efficacy update on leflunomide (Arava). URL:
  • 13
    Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol 2004; 31: 190611.
  • 14
    Cannon GW, Finck BK, the Enbrel ERA Investigator Group, Simpson KM, the Leflunomide Investigators Group, Strand V. Methotrexate-induced pulmonary disease during treatment of rheumatoid arthritis in large clinical trials [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S341.